We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -0.75 (-1.78%)
Spread: 1.00 (2.439%)
Open: 42.25
High: 42.25
Low: 41.25
Prev. Close: 42.25
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UltraDEX advertising launch

10 Oct 2016 07:00

RNS Number : 0358M
Venture Life Group PLC
10 October 2016
 

Venture Life Group plc

("Venture Life" or the "Company")

 

UltraDEX advertising launch

 

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces the launch of the new UltraDEX advertising campaign in the UK.

 

Since the acquisition of the UltraDEX oral care products range in March 2016, the Company has revitalised the brand, creating a fresh identity and a clearer message on all advertising material and packaging. The range is comprised of a daily oral rinse, toothpaste, oral spray and other inter-dental accessories, and achieved revenues of £1.4 million in the first six months of 2016. The Company's Brands business now represents 20% of its total revenue and the Company remains confident in the growth prospects for UltraDEX, in addition to its other brands, having signed three new distribution agreements for UltraDEX since acquiring it in March 2016.

 

The campaign, launching today, will run for two weeks and aims to increase brand awareness and encourage product trial among new users. UltraDEX will feature on approximately 4,000 tube cards on the London Underground, meaning a banner advertisement in every train carriage on every line, as well as cross track posters in 91 Underground stations. In conjunction with this, the Company will run an extensive radio campaign in London and the South East and free UltraDEX samples will be given out at Waterloo, Victoria and Liverpool Street stations. A new website (www.ultradex.co.uk) has also been launched and whilst the overall level of advertising is significant for Venture Life it is in line with budgeted plans. It will also support in-store activity amongst Venture Life's key retail partners such as Boots, Tesco, Sainsbury's and Amazon, as the Company continues to grow the retail presence of the brand.

 

Commenting, Chief Executive Officer of Venture Life, Jerry Randall, said: "The acquisition of UltraDEX has had a big impact on our Brands business and we are expecting it to make a significant contribution towards Group profitability. This campaign is being run initially in the London and South East region as we continue to invest behind the UltraDEX brand and support our retail partners."

 

If any investors would like a sample of the UltraDEX products, please contact Walbrook PR using the contact details below.

 

For further information, please contact:

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

 

James Hunter, Chief Financial Officer

 

 

 

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Freddy Crossley/Peter Steel/Duncan Monteith (Corporate Finance)

 

Tom Salvesen (Corporate Broking)

 

 

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

James Pope/Ben Turner

 

 

Walbrook PR

venturelife@walbrookpr.com or +44 (0) 20 7933 8780

Paul McManus/Anna Dunphy

+44 (0) 7980 541 893 / +44 (0) 7876 741 001

 

 

 

About Venture Life (www.venture-life.com)

 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.

 

The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAZDLFBQBFEFBE
Date   Source Headline
19th Apr 20247:00 amRNSRCF in Place and New Partner in the USA
9th Apr 20247:00 amRNSFinal Results for year ended 31 December 2023
4th Apr 20247:00 amRNSNotice of Results and Investor Presentation
19th Feb 20245:18 pmRNSHolding(s) in Company
6th Feb 202410:48 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSTrading Update
20th Dec 20232:00 pmRNSHolding(s) in Company
28th Nov 202312:28 pmRNSHolding(s) in Company
22nd Nov 20234:05 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSChange of Nominated Adviser and Broker
31st Oct 20233:11 pmRNSHolding(s) in Company
17th Oct 20231:54 pmRNSHolding(s) in Company
25th Sep 20237:01 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSTrading Statement
5th Jul 20237:00 amRNSPDMR Shareholdings – Grant of Awards
26th Jun 20234:48 pmRNSDirector/PDMR Shareholding
25th May 20231:54 pmRNSDirector Dealings
22nd May 20233:01 pmRNSResults of AGM
22nd May 20237:00 amRNSAGM Statement
19th May 20237:00 amRNSBoard Change
9th May 20237:00 amRNSNotice of Capital Markets Event
28th Apr 202310:05 amRNSAnnual Report and Notice of AGM
5th Apr 20231:53 pmRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSFinal Results for year ended 31 December 2022
31st Mar 20237:00 amRNSInvestor Presentation
13th Mar 20237:00 amRNSUpdate re Revolving Credit Facility
10th Mar 20232:05 pmRNSSecond Price Monitoring Extn
10th Mar 20232:00 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSTrading Statement
9th Jan 20237:00 amRNSLicensing and distribution agreements
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn
1st Dec 20224:37 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSAcquisition and trading update
10th Oct 20227:00 amRNSDirectorate Changes
23rd Sep 202211:08 amRNSInvestor Presentation
22nd Sep 20227:00 amRNSHalf-year Report
25th Jul 202212:00 pmRNSDirector/PDMR Shareholding
25th Jul 20227:00 amRNSTrading Update
20th Jun 20222:31 pmRNSResults of AGM
10th Jun 202212:21 pmRNSDirector/PDMR Shareholding
9th Jun 20225:53 pmRNSAnnual Report & Notice of AGM - Correction
7th Jun 20227:00 amRNSAnnual Report & Notice of AGM
30th May 20224:22 pmRNSDirector/PDMR Shareholding
30th May 20227:00 amRNSDirectorate Changes
23rd May 20224:27 pmRNSHolding(s) in Company
20th May 20227:00 amRNSInvestor Presentation
17th May 20227:00 amRNSDirectorate Changes
17th May 20227:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.